A study conducted in Argentina showed that the booster dose with the Sputnik-Light vaccine elicits a strong immune response, the Russia Direct Investment Fund said in a post on its official Twitter account.
“The world’s first combined study conducted in Argentina with the support of RDIF showed that the Sputnik-Light and Moderna vaccines as booster doses elicited a strong immune response,” the statement said. “The combination of AstraZeneca and Sputnik-Light had an excellent result”, it is also stressed.
According to data from the Gamalei Institute in Moscow, which developed the Sputnik-V vaccine, the effectiveness of Sputnik-Light (which is the first dose of Sputnik-V) against the Delta variant reaches 70% over a period of three months. after vaccination.
In the age group up to 60 years, the effectiveness of the vaccine exceeded 75%. At the same time, the efficacy indices of Sputnik-Light against the “Delta” variant exceed the corresponding indices of the two-dose foreign vaccine series, which show a significant reduction in efficacy of up to less than 50% five months after vaccination.
The researchers also published a comparative table that looked at the interaction of vaccines from different manufacturers. According to the table, those who took the two doses of Sputnik-V had a better immune response with Sputnik-Light and Moderna as booster doses. In those who received the two doses of the AstraZeneca vaccine, all antibody types increased with the booster dose of the AstraZeneca and Moderna vaccines.
The Sputnik-Light vaccine was approved in Russia on August 11, 2020. The vaccine is currently approved in 70 countries with a total population of 4 billion people.